Stocktoria

Elicio Therapeutics, Inc. ELTX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-02-05

Elicio Therapeutics, Inc. statistics & valuation

Market cap$76.3M
P / B46.7×
Net cash$8.6M
Enterprise value USD$67.8M
Earnings yield EBIT/EV-55.6%
Return on capital-212.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
-1919.20% -138.80% -1031.40% 202020212022202320242025
Return on equity (%)
-309.50% -2418.80% 202020212022202320242025
Shares outstanding
15.3M 30.0M 320281 9.6M 12.2M 17.8M 202020212022202320242025
Net debt ($)
-$34.0M -$88.8M $2.4M -$8.6M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-169.20% -56.50% -124.50% -129.70% -184.20% -153.00% 202020212022202320242025
Free cash flow margin (%)
-796.10% -187.30% -992.30% 202020212022202320242025
Debt / equity (×)
6.11× 202020212022202320242025
EPS ($)
-$5.43 -$1.93 -$89.27 -$6.96 -$4.25 -$2.58 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin———-1031.4%-138.8%-1919.2%
Net margin———-1225.9%-192.8%-2781.5%
FCF margin———-992.3%-187.3%-796.1%
Return on assets-153.0%-184.2%-129.7%-124.5%-56.5%-169.2%
Return on equity-2418.8%458.8%-309.5%27.6%73.2%88.6%
Debt / equity6.11×-1.77×——-0.00×-0.01×
Current ratio2.381.801.681.568.080.39

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.